X0708 D LIVE 0001614744 Kitov Pharmaceuticals Holdings Ltd. ONE AZRIELI CENTER ROUND BUILDING TEL AVIV L3 ISRAEL 6701101 97239333121 ISRAEL Mainrom Line Logistics Ltd. None Other Limited company true Isaac Israel One Azrieli Center Round Building Tel Aviv L3 ISRAEL 6701101 Executive Officer Director Chief Executive Officer and Director of the Issuer John Paul Waymack One Azrieli Center Round Building Tel Aviv L3 ISRAEL 6701101 Executive Officer Director Chief Medical Officer and Chairman of the Board of Directors Simcha Rock One Azrieli Center Round Building Tel Aviv L3 ISRAEL 6701101 Executive Officer Director Chief Financial Officer and Director Steven Steinberg One Azrieli Center Round Building Tel Aviv L3 ISRAEL 6701101 Director Director Ido Agmon One Azrieli Center Round Building Tel Aviv L3 ISRAEL 6701101 Director Director Arye Weber One Azrieli Center Round Building Tel Aviv L3 ISRAEL 6701101 Director Director Ran Tzror One Azrieli Center Round Building Tel Aviv L3 ISRAEL 6701101 Director Director Revital Stern-Raff One Azrieli Center Round Building Tel Aviv L3 ISRAEL 6701101 Director Director Gil Ben-Menachem One Azrieli Center Round Building Tel Aviv L3 ISRAEL 6701101 Executive Officer Director Vice President of Business Development Avraham Ben-Tzvi One Azrieli Center Round Building Tel Aviv L3 ISRAEL 6701101 Executive Officer Group Chief Legal Officer Hadas Reuveni One Azrieli Center Round Building Tel Aviv L3 ISRAEL 6701101 Executive Officer Founder and Chief Technology Officer of TyrNovo Pharmaceuticals Decline to Disclose 06b false 2017-07-11 false true false 0 Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC 375 None None 430 PARK AVENUE 4TH FLOOR NEW YORK NY NEW YORK 10022 CA CALIFORNIA IL ILLINOIS NJ NEW JERSEY NY NEW YORK false 1981005 1981005 0 Represents the aggregate amount received from investors in connection with Issuer's registered offering of ADSs and concurrent private placement of warrants, respectively, which were issued jointly to investors for a single purchase price. false 14 138670 0 Represents 6% commission and 1% management fee of gross proceeds from investors for sale of ADSs and warrants in the registered offering and concurrent private placement. We will also pay expenses up to $75,000 and issued an unregistered warrant. 0 false Kitov Pharmaceuticals Holdings Ltd. /s/ Simcha Rock Simcha Rock Chief Financial Officer and Director 2017-08-08